ImmuPharma (LON:IMM) Trading 27.3% Higher – Time to Buy?

ImmuPharma plc (LON:IMM) shares shot up 27.3% during mid-day trading on Friday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,056,761 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 8,429,979 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Performance

The company’s 50 day moving average price is GBX 7.92 and its 200-day moving average price is GBX 4.37. The company has a market cap of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53.

ImmuPharma (LON:IMM) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.